The inferior prognosis of CRC patients expressing low IGFBP3 or high levels of IGFBP2 suggests that IGFBPs are also implicated in CRC tumorigenesis, either operating as negative regulators of IGFs activity or exerting IGF-independent effects on cancer growth. Here, IGFBP3 is linked to cancer.